Roivant Sciences Ltd.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2020 | — | $2.09B | $2.27B |
| Jun 2020 | — | $2.27B | $2.31B |
| Sep 2020 | — | $2.41B | $2.39B |
| Dec 2020 | — | $2.17B | $2.15B |
| Mar 2021 | $170.3M | $1.80B | $2.06B |
| Jun 2021 | $186.4M | $1.72B | $2.00B |
| Sep 2021 | $199.9M | $2.04B | $2.50B |
| Dec 2021 | $204.0M | $1.87B | $2.21B |
| Mar 2022 | $210.0M | $1.66B | $2.06B |
| Jun 2022 | $383.7M | $1.38B | $1.94B |
| Sep 2022 | $376.1M | $1.16B | $1.60B |
| Dec 2022 | $375.1M | $955.5M | $1.53B |
| Mar 2023 | $375.5M | $1.16B | $1.68B |
| Jun 2023 | $385.1M | $910.7M | $1.43B |
| Sep 2023 | $389.4M | $948.5M | $1.41B |
| Dec 2023 | $403.3M | $6.09B | $6.67B |
| Mar 2024 | $430.6M | $5.97B | $6.49B |
| Jun 2024 | $311.7M | $5.44B | $5.68B |
| Sep 2024 | — | $5.15B | $1.96B |
| Dec 2024 | — | $5.19B | $1.99B |
| Mar 2025 | — | $4.69B | $2.72B |
| Jun 2025 | — | $4.35B | $1.24B |
| Sep 2025 | — | $4.36B | $1.24B |
| Dec 2025 | — | $4.27B | $1.48B |
| Mar 2026 | — | $4.53B | $1.42B |
| Jun 2026 | — | $4.23B | $1.25B |